Bevacizumab-associated osteonecrosis of the jaw
Authors:
Open Access
- 31 October 2008
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 19 (12) , 2091-2092
Abstract
A 63-year-old woman suffered a local relapse of breast cancer. Baseline bone scan was normal and she had never received bisphosphonates previously. While being treated with liposomal doxorubicin and bevacizumab, she experienced left-sided maxillary pain after 1 month of therapy. A tooth infection was diagnosed and teeth number 25 and 26 were extracted. One month later, a mouth-antrum fistula was surgically revised and occluded. Shortly afterward the patient suffered from a trigeminal neuralgia. X-ray and computed tomography scan showed maxillary sinusitis and signs of osteonecrosis of the jaw (ONJ; Figure 1). The jaw lesion was carefully extirpated and the maxillary sinus was drained. Histological work-up verified the clinical diagnosis of ONJ, and an infiltration from the cancer was excluded. At 3 months of follow-up, the patient remains free of lesions and symptoms.Keywords
This publication has 6 references indexed in Scilit:
- Bevacizumab-associated osteonecrosis of the jawAnnals of Oncology, 2008
- Osteonecrosis of the Jaw Related to BevacizumabJournal of Clinical Oncology, 2008
- Distal phalange necrosis: A severe manifestation of palmar plantar erythrodysesthesiaAmerican Journal of Obstetrics and Gynecology, 2006
- Systematic Review: Bisphosphonates and Osteonecrosis of the JawsAnnals of Internal Medicine, 2006
- Bisphosphonates: new antiangiogenic molecules in cancer treatment?Annals of Oncology, 2003
- The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal AntibodiesGrowth Factors, 1992